What is Theranostics?
image courtesy: GE HealthCare

What is Theranostics?

Theranostics is a combination of the terms?therapeutics and diagnostics?and describes the combination of using one radioactive drug to identify (diagnose) and a second radioactive drug to deliver therapy to treat the main tumor and any metastatic tumors.

With the evolution of advanced imaging technologies, and the continuous search to discover new tracers for targeted therapies, industry leaders such as GE Healthcare are fortifying the entire molecular imaging pathway, from providing access to emerging molecules to continuing to push the limits of molecular imaging with PET/computed tomography (CT) and SPECT/CT technologies. Innovations in molecular imaging technology introduce much more imaging data for processing and include highly sophisticated automated tools and artificial intelligence (AI)-based reconstruction algorithms to assist clinicians as they render complex diagnoses. Molecular imaging is essential in theranostics, allowing for non-invasive, repetitive assessment of the compound uptake and allowing for characterization of the tumor tissue, and therapy response over time.

In this data-rich environment, theranostic target pairs have been developed, validated, and successfully used in treating lymphomas, neuroblastoma, neuroendocrine tumors and more recently, certain prostate cancers.[1]?Strong clinical need in areas such as prostate and other cancers continue to fuel the search for additional diagnostic and therapeutic pairings with the goal of improving quality of life and outcomes for cancer patients.


Success with theranostics in prostate cancer?

When clinically relevant prostate cancer is found and treated at an early stage before metastasis has occurred, treatments such as prostate cancer surgery and radiation often result in improved survival.[2]?Worldwide,?however, prostate cancer?is the most commonly diagnosed?male malignancy?and the fourth?leading?cause of cancer death in?men.[3]?Current screening methodologies for prostate cancer include blood test to quantify prostate-specific antigen (PSA), or hormone levels and common treatments include radical prostatectomy combined with radiation therapy, however, this route is not always a possibility due in part to the complex process required to detect tumors.1

Despite advances in treating prostate cancer, certain prostate cancer types, called castrate- or hormone-resistant, continue to grow even when the patients’ hormone levels reach beyond the established low threshold.[4]?Theranostics efforts are centered around treating these more lethal, castrate-resistant prostate cancers. The treatment combines a targeting compound or ligand with a radioactive particle which is injected into the patient and targets the cancer cells.

Because it is highly expressed in more than 95 percent of prostate cancers, prostate specific membrane antigen (PSMA) is one of the emerging diagnostic and theranostic biomarkers for prostate cancer detection as well as targeted therapies[5]?and is a predictive biomarker for prostate cancer.[6]?Clinicians monitor treatment-induced metabolic changes to the tumor, which serves to indicate the likelihood of successful response to treatment. Targeting PSMA in theranostics efforts can help impact clinical management decisions and identify patients who may receive the greatest benefit from targeted therapies.

The FDA recently approved a new lutetium-based therapy, referred to as?177Lu-PSMA-617, based on the results of the Phase III VISION clinical trial.[7]?The treatment is for adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC), who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy. Many other small molecules and antibodies targeting PSMA have been developed and labeled, such as?177Lu,?161Tb,?131I,?90Y,?67Cu,?47Sc, and are currently being studied in preclinical and clinical studies.[8]


Supporting the growing field of molecular imaging and radiopharmaceuticals

With the long-term success of PET imaging biomarker 18F-FDG (FDG) in oncology, and newly approved therapies such as?177Lu-PSMA-617, many other useful diagnostic and theranostic biomarker discoveries are likely to gain approval for clinical use to support personalized treatments and improved outcomes. As utilization of molecular imaging technology expands, clinical interest in new radiopharmaceuticals is continuously growing.[9]?An important aspect of introducing these new tracers is the ability to produce and distribute them so clinicians have access to them.

As a leader in the molecular imaging and radiopharmaceutical industry, GE Healthcare supports the continued discovery and production of new tracers and therapies with powerful tools to streamline their production.

Cyclotrons, PET radiochemistry systems and tracer?production facility solutions are required to deliver FDG to a large number of clients or supply a research program with a wide range of tracers. Having this support facilitates the efficiency required to work within clinical schedules, the flexibility needed for research protocols and the performance necessary to meet distribution demands.

?

Connecting every step in molecular imaging, from discovery to treatment.?

The reliance on molecular imaging techniques such as?PET/CT?and?SPECT/CT?to provide clinicians quantitative data about metabolic tumor characterization, combined with knowledgeable clinicians to acquire, interpret and monitor treatment effectiveness are the keys to the future of and potential for theranostics to become standard of care. PET imaging, for example, can interrogate the whole body for the expression of therapeutic targets.[10]?The presence and degree of target expression are associated with a therapy response. Thus, PET imaging probes have been introduced as predictive biomarkers.[11]?

Advances in molecular imaging hardware and software continue to facilitate improvements in clinician workflow as well as improvements in exam duration and facilitating interpretation of studies. The introduction of AI and deep learning-based tools also assist with image classification. Experts believe, however, that due to the complexities of molecular medicine, more training is critically important and urgently needed to integrate these approaches into patient management and maintain an optimistic outlook for the growth of the specialty and opportunities in molecular diagnostics and treatment.[12]

?

Bright future for theranostics and precision medicine

Theranostics?is an attractive and quickly developing therapy option for a variety of cancers, such as lymphoma, melanoma, neuroendocrine tumor and prostate cancer. Industry partners such as GE HealthCare continue to support clinicians’ search for new biomarkers and therapies with data rich, high quality diagnostic imaging and image processing tools for tumor characterization and evaluating therapy response. Theranostics approaches, as they are transitioned to standard of care and more widely accessible, have the potential to successfully improve the management and outcomes of patients affected by many cancers, as well as future possible applications in other clinical areas.?

?

REFERENCES

[1]?https://jnm.snmjournals.org/content/61/Supplement_2/263S

[2]?Artificial intelligence at the intersection of pathology and radiology in prostate cancer. Diagnostic Interventional Radiology Journal https://www.dirjournal.org/sayilar/103/buyuk/183-188.pdf Accessed 6/13/2019

[3]?Leslie SW, Soon-Sutton TL, Sajjad H, et al. Prostate Cancer. [Updated 2022 Feb 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-.?Available from: https://www.ncbi.nlm.nih.gov/books/NBK470550/

[4]?https://cancer.ca/en/cancer-information/cancer-types/prostate/treatment/castration-resistant-prostate-cancer#:~:text=Castration%2Dresistant%20prostate%20cancer%20(CRPC,or%20hormone%2Dresistant%20prostate%20cancer.

[5]?Rahbar A.B., Afshar-Oromieh A., Jadvar H., Ahmadzadehfar H. PSMA Theranostics: Current Status and Future Directions. Mol. Imaging. 2018;17:1536012118776068. doi: 10.1177/1536012118776068.

[6]?Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.

[7]?https://news.ohsu.edu/2022/03/29/ohsu-researchers-instrumental-in-studying-newly-fda-approved-treatment-for-a-form-of-prostate-cancer#:~:text=The%20FDA%20recently%20approved%20a,Phase%20III%20VISION%20clinical%20trial.

[8]?https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918517/#

[9]?https://jnm.snmjournals.org/content/52/Supplement_2/36S

[10]?Reubi JC, Maecke HR. Approaches to multireceptor targeting: hybrid radioligands, radioligand cocktails, and sequential radioligand applications. J Nucl Med. 2017;58(suppl):10S–16S.

[11]?https://jnm.snmjournals.org/content/60/Supplement_2/3S

[12]?https://jnm.snmjournals.org/content/60/Supplement_2/3S

Louise Jefferies

Helping introverted scientists to speak up with confidence and become more visible without becoming overwhelmed.

1 年

fantastic developments

Michael J. Murphy

Associate Wealth Consultant ~Stockbroking, Financial Advice QFA LIB EFA AFP

1 年

Thanks for sharing ?? #cancer #diagnostics #innovation

Gary Mc Nulty

Radiographer (Paediatrics)

1 年

Has this not been around for a long time...? E.g. using SPECT to identify MIBG avid neuroblastoma mets and using MIBG to treat the same... only for the disease to become refractory at some point in high risk cases? Is Theranostics currently futile in curing high risk neuroblastoma mets or have there been new radiopharmaceuticals developed/ tested that I am unaware of that will work? I know immunotherapy meds like dinutuximab have been successful in treating high risk neuroblastoma mets for a 5 year period post treatment.

Baraka J. Fundo

NM Physicist | Author #AmaniRafikiShujaa

1 年

Interesting! Its potential to improve patient outcomes and optimize treatment strategies is indeed praiseworthy.

David Perrin

Chemistry Professor, University of British Columbia

1 年

Very important concept; examples of theranostic are DOTA-peptides where the same molecule is used for imaging and therapy. Yet the 68Ga-chelate (used for diagnostic PET) is not biochemically identical to the 177Lu-chelate (used for therapy). Also worth noting: 18F is a superb isotope for diagnostic PET in terms of resolution and economic distribution. While theranostic pairs need not be the identical molecule e.g. 18F-Pylarify and 177Lu-Pluvicto represent a superb example of such a successful theranostic pair, to circumvent the need for theranostic radiometal pairs while accessing 18F for PET, we and a few others have been focusing on dual isotope hot-cold/cold-hot "true theranostics". Ostensibly, the 18F-isotopolog is metallated with a non-radioactive metal for PET imaging, while the 19F-isotopolog is then radiometallated for therapy. Such "radiohybrids" differ only in atomic weights and are otherwise chemically identical across both diagnostic and therapeutic regimes. Benefiting from the excellent resolution of 18F-PET, these could potentially maximize the chance for treating what you are seeing. See: https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cbic.201900632

  • 该图片无替代文字

要查看或添加评论,请登录

Mathias Goyen, Prof. Dr.med.的更多文章

社区洞察

其他会员也浏览了